Sepsis Clinical Trial
Official title:
Prospective Evaluation of Sepsis Prediction Algorithms in a Multi-Hospital Healthcare System
Sepsis is a severe response to infection resulting in organ dysfunction and often leading to death. More than 1.5 million people get sepsis every year in the U.S., and 270,000 Americans die from sepsis annually. Delays in the diagnosis of sepsis lead to increased mortality. Several clinical decision support algorithms exist for the early identification of sepsis. The research team will compare the performance of three sepsis prediction algorithms to identify the algorithm that is most accurate and clinically actionable. The algorithms will run in the background of the electronic health record (EHR) and the predictions will not be revealed to patients or clinical staff. In this current evaluation study, the algorithms will not affect any part of a patient's care. The algorithms will be deployed across the Emory healthcare system on data from all patients presenting to the emergency department.
Status | Not yet recruiting |
Enrollment | 1200 |
Est. completion date | December 2024 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - All adult patients admitted through the ED Exclusion Criteria: - None |
Country | Name | City | State |
---|---|---|---|
United States | Emory Healthcare System | Atlanta | Georgia |
United States | Emory Hospital | Atlanta | Georgia |
United States | Emory Midtown Hospital | Atlanta | Georgia |
United States | Emory Saint Joseph's Hospital | Atlanta | Georgia |
United States | Emory Decatur Hospital | Decatur | Georgia |
United States | Emory Johns Creek Hospital | Johns Creek | Georgia |
United States | Emory Hillandale Hospital | Lithonia | Georgia |
Lead Sponsor | Collaborator |
---|---|
Emory University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Patient hospitalization-level area under curve (AUC) for identification of sepsis, | Definition of Sepsis using the Centers for Disease Control and Prevention (CDC) Adult Sepsis Surveillance. | Duration of hospital stay (until discharge or death), an expected average of 30 days | |
Secondary | Sensitivity, specificity, and Positive and Negative Predictive Value of algorithms | Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). | Duration of hospital stay (until discharge or death), an expected average of 30 days | |
Secondary | Lead time to antibiotic administration | The time between the initial deployment of the alert in patients confirmed to have sepsis (ture positives) and the physician's ordering of intravenous antibiotic therapy. | Duration of hospital stay (until discharge or death), an expected average of 30 days | |
Secondary | Percent expected increase in unnecessary antibiotics | Percent of patients who were incorrectly identified as having sepsis (false positives), and received antibiotics. | Duration of hospital stay (until discharge or death), an expected average of 30 days | |
Secondary | Number needed to screen | The number of alerts that would need to be processed to find one true positive sepsis. | Duration of hospital stay (or death), an expected average of 30 days | |
Secondary | Number of Total and false alert burden | The number of Total and false alert burden cumulative across all study patients over the study period | Duration of hospital stay (until discharge or death), an expected average of 30 days | |
Secondary | Time-horizon based AUCs | AUCs will be calculated at 3 pre-specified time horizons. | 4 hours, 8 hours, and 24 hours | |
Secondary | Accuracy and calibration by subgroup | The AUC and calibration curves will be compared by sex and race to ensure predictive accuracy is equal across subgroups. | Duration of hospital stay (until discharge or death), an expected average of 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |